Nasdaq's New $5 Million Market-Value Floor Has No Cure Period, and a Reverse Split Does Not Lift It

by Renée Delacroix · August 28, 2026

Senior Analyst, The MicroCap Herald

The rule that will matter most to the smallest companies on Nasdaq this year is not a bid-price rule. It is a market-value rule, and its distinguishing feature is that it does not come with the grace period that micro-cap boards have spent a decade learning to manage.

On July 22, 2026 the Securities and Exchange Commission approved a Nasdaq proposal adopting a new continued listing requirement. The order was issued as Release No. 34-105971 under File No. SR-NASDAQ-2026-004 and published in the Federal Register on July 27, 2026 at 91 FR 46995. The new provisions are Nasdaq Rules 5450(a)(3) and 5550(a)(6).

What the rule does

A listed company must maintain a market value of listed securities of at least $5 million. The order works from Nasdaq's existing definitions: Rule 5005(a)(23) defines market value as the consolidated closing bid price multiplied by the measure to be valued, and Rule 5005(a)(22) defines listed securities as those listed on Nasdaq or another national securities exchange. The requirement reaches all three tiers — Rule 5450(a)(3) covers the Nasdaq Global Select Market and the Nasdaq Global Market, and Rule 5550(a)(6) the Nasdaq Capital Market. Writing in Life Science Leader on Aug. 21, Driscoll R. Ugarte described the measure in the same terms.

Fall below the threshold for 30 consecutive business days and the exchange issues a Staff Delisting Determination, with immediate suspension and delisting under Rule 5810(c)(1). There is no automatic cure period attached to that determination.

The second half of the mechanism is the part that inverts the familiar pattern. Under Rule 5815(a)(1)(B), the order provides that "a timely request for a hearing will not stay the suspension of the securities from trading pending the issuance of a written Hearings Panel decision where the company received a Staff Delisting Determination due to a failure to comply with the MVLS Requirement." The carve-out is specific to this standard. A company that appeals an MVLS determination still comes off the exchange while the appeal runs, and its shares trade over the counter during the Hearings Panel's review.

The Panel retains authority under Rule 5815(c)(1)(I), and the order contemplates that it may grant an exception for a period not to exceed 180 days from the Staff Delisting Determination for the company to demonstrate that it meets all requirements for initial listing. That is a meaningful distinction: the route back runs through the initial listing standards, which are a higher bar than the continued listing standards a company has already failed.

How many companies this reaches

The SEC's order includes an analysis of how many issuers would have failed the requirement had it been in force. The figure "increased sharply from 2 issuers in 2021 to 140 issuers in 2023," then eased to 122 in 2024 and 91 in 2025.

Read plainly, that series says two things at once. The exposed population has come down from its 2023 peak, and it remains roughly forty-five times what it was in 2021. The rule is being introduced against a base of small listings materially larger than the one the exchange's prior regime was calibrated for.

Why the usual remedy does not apply

When a micro cap breaches Nasdaq's $1.00 minimum bid price, the standard response is a reverse split. It works because the deficiency is measured in price per share, and a consolidation raises price per share directly.

Market value of listed securities is measured differently. It is price multiplied by share count. A reverse split at a ratio of one-for-N multiplies the price by N and divides the share count by N, so the product is, before any market reaction, unchanged. A company that consolidates its stock to clear the bid-price rule has done nothing to its market value of listed securities. That is this desk's arithmetic from the definition in the order, not a conclusion the order states.

The two standards also differ in tempo. Bid-price deficiencies arrive with compliance periods and, in defined circumstances, extensions of them. The market-value standard as approved arrives with a 30-business-day observation window and then a determination that is not stayed by an appeal. A board that has budgeted its planning around the rhythm of the bid-price rule is working from the wrong clock.

The other exchange

NYSE American has moved in the same direction on both ends of the listing, though only one of the two changes is final. On the continued listing side, Ugarte's Life Science Leader piece reports that the exchange filed a comparable standard in December 2025 requiring a minimum $5 million average global market capitalisation over a consecutive 30-trading-day period, withdrew an amendment in March 2026 and refiled a substantially similar $5 million standard, which was still pending before the SEC when that piece was published on Aug. 21. It is a proposal, not a rule in force. The same account reports one process difference: the NYSE American proposal preserves an issuer's right to appeal a delisting determination to a committee of the exchange's board, which may allow a company to keep trading while it appeals, where the Nasdaq rule suspends first.

On the initial listing side, Andrew B. Stewart and Jun Ho Song of Cozen O'Connor wrote on May 12, 2026 that the SEC approved amendments to Sections 101 and 102 of the NYSE American Company Guide by way of a Federal Register notice dated April 1, 2026. Unrestricted public float under Standard 1 rose from $3 million to $15 million; Standard 4 remained at $20 million; stockholders' equity under Standard 2 rose from $4 million to $5 million; and the minimum share price was set at $4.00, replacing prior $2.00 and $3.00 thresholds. For initial public offerings and other underwritten offerings, that account says, issuers must now meet the minimum float requirement using shares sold in the offering itself, and can no longer rely on pre-existing shareholders to satisfy it.

Taken together, the picture for a company at the bottom of the US listed market in 2026 is a higher on-ramp and a faster exit. Getting listed on NYSE American now demands more float, more equity and a higher share price than it did last year, and falling out of compliance on Nasdaq's market-value standard removes the cushion that made deficiency notices a manageable, months-long process.

A live example ran on Friday. Cycurion Inc., which received a Nasdaq delisting determination letter dated July 10 over the $1.00 bid price and appealed it, put a 1-for-8 reverse split into effect on Aug. 28. That addresses the price test and not the market-value test. Where Cycurion actually stands against the $5 million floor is not something this desk can state: the secondary figures available to it disagree, with a GuruFocus item dated July 30 putting its market capitalisation at approximately $5 million and the StockTitan page carrying the Aug. 26 split announcement showing $16.10 million for that session. Neither has been checked against a filing. What holds regardless of the level is the arithmetic: the split does not move that measure in either direction.

Two caveats on sourcing. The Nasdaq figures and rule citations above come from the SEC's own approval order, which this desk retrieved. The NYSE American details come from the two published summaries cited below; the full text of the NYSE American filings was not reviewed for this article.